Biofrontera Inc Warrants (27/10/2026) BFRIW 深 滬
等待開盤 02-14 09:30:00 美东时间
0.0501
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0501
- 總市值 0
- 52周最高 0.277
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.0251
- 委 比 -88.48%
- 總股本 --
- 歷史最高 9.18
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.005
- 每 手 1
- 風險率 0.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biofrontera Announces Results From 172 Participants In Its Phase 3 Cliical Study Of Ameluz Photodynamic Therapy To Treat Actinic Keratoses
Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced positive and
02-09 22:16
Biofrontera meldet erfolgreiche Phase-3-Studie für Ameluz bei aktinischer Keratose an Extremitäten, Hals und Rumpf
Biofrontera meldet erfolgreiche Phase-3-Studie für Ameluz bei aktinischer Keratose an Extremitäten, Hals und Rumpf Biofrontera Inc. hat positive und statistisch signifikante Top-Line-Ergebnisse aus einer Phase-3-Studie zur Wirksamkeit und Verträglichkeit von Ameluz® Photodynamischer Therapie (PDT) b
02-09 22:15
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
Biofrontera Inc. announced positive Phase 3 clinical trial results for Ameluz® PDT in treating mild to moderate actinic keratosis (AK) on extremities, neck, and trunk. The study met its primary endpoint with statistically significant results, showing 45.6% complete clearance in the Ameluz® group versus 16.7% in the vehicle group (p < 0.0003). Ameluz® demonstrated high efficacy, favorable cosmetic outcomes, and high patient satisfaction. The compa...
02-09 14:15
Biofrontera Expects Q4 Revenue Between $17M - $17.5M, FY25 Revenue Between $41.5M - $42M
Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced preliminary unaudited revenue results for the fourth quarter
01-13 21:31
Biofrontera Locks Databases For Treatment Phase Of Phase 3 Clinical Trial Of Ameluz PDT, Phase 2 Clinical Trial To Treat Moderate To Severe Acne Vulgaris
Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT), today announced the successful database
01-08 21:48
Biofrontera Inc. Announces Data Base Locks for Two Clinical Studies Supporting Key Data and Regulatory Milestones
Biofrontera Inc. successfully locked databases for two clinical studies evaluating Ameluz PDT for treating actinic keratosis (AK) and acne vulgaris on January 5, 2026. These milestones support key regulatory events and aim to expand Ameluz's approved uses in the U.S. AK and acne are the most common skin disorders in the U.S., impacting tens of millions annually. Positive Phase 3 AK study results could lead to an sNDA submission in Summer 2026 to ...
01-08 13:45
Biofrontera Transfers Of Ameluz, RhodoLED New Drug Applications, Investigational New Drug Applications; Completes Requirements For Transfer Of All U.S., Some Global Intellectual Property Associated With Ameluz And RhodoLED
Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera" or the "Company"), a leader in photodynamic therapy (PDT) development and commercialization, today announced the completion of the transfer of the FDA approvals for
2025-12-18 21:54
Biofrontera Files sNDA For Ameluz-PDT To Treat sBCC After Phase 3 Trial Achieves 65.5% Complete Clearance Of Main Target Lesions; Primary And Key Secondary Endpoints Met With High Statistical Significance With Favorable One-Year Recurrence and Aesthetic Outcomes
sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to FDAPrimary and key
2025-12-02 21:48
Biofrontera Q3 EPS $(0.62) Misses $(0.58) Estimate, Sales $6.988M Miss $7.000M Estimate
Biofrontera (NASDAQ:BFRI) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.58) by 6.9 percent. This is a 36.73 percent increase over losses of $(0.98) per share from the
2025-11-13 05:43
